Tirzepatide for Diabetes and Beyond: SURMOUNT/SURPASS Results and Cardiovascular Potential | Research

The takeaway

Review of SURMOUNT and SURPASS trial data shows tirzepatide reduces HbA1c by up to 2.24% and body weight by up to 11.2 kg, with promising cardiovascular health applications under investigation.

Up to 2.24% HbA1c reduction
Tirzepatide's dual GLP-1/GIP mechanism achieves greater glycemic improvements than single-receptor agonists across SURPASS trials

What the researchers found

Tirzepatide across SURMOUNT/SURPASS trials achieved HbA1c reductions up to 2.24% and weight loss up to 11.2 kg with good tolerability. Cardiovascular benefits are promising based on surrogate markers but await dedicated outcome trials.

Why it matters

Tirzepatide represents a new class of dual-receptor agonists that outperforms single GLP-1 agonists. Understanding its full clinical profile — including cardiovascular effects — is essential as it becomes a first-line treatment option for T2DM and obesity.

The numbers in context

Maximum HbA1c reduction: 2.24%. Maximum weight loss: 11.2 kg. Good tolerability across trials.

How the study worked

Narrative review summarizing results from the SURMOUNT and SURPASS clinical trial programmes, evaluating efficacy, safety, and cardiovascular implications of tirzepatide.

Who was studied

SURMOUNT and SURPASS trial participants

What this study cannot tell us

Review article dependent on published trial data. Cardiovascular outcomes from dedicated CVOTs are not yet available. Long-term safety beyond trial durations is unknown. Cost and access remain barriers.

How to read the evidence

Strong evidence from review of multiple large-scale randomized clinical trials (SURMOUNT and SURPASS programmes). Cardiovascular-specific evidence awaits dedicated outcome trials.

When this study was published

Published in 2024; synthesizes the most current clinical trial evidence for tirzepatide.

The bigger picture

The dual GLP-1/GIP mechanism of tirzepatide may explain its superior efficacy over GLP-1-only drugs. If cardiovascular outcome trials confirm the cardioprotective effects suggested by metabolic improvements, tirzepatide could become the standard of care for T2DM with cardiovascular risk.

Questions still open

Will tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) show reduced cardiovascular events?
How does tirzepatide's cardiovascular profile compare head-to-head with semaglutide?
Are the cardiovascular benefits driven by weight loss, metabolic improvements, or direct vascular effects?

Common questions

Is tirzepatide better than semaglutide?

In head-to-head comparisons (SURPASS-2), tirzepatide at higher doses showed greater HbA1c reduction and weight loss than semaglutide 1 mg. The dual GLP-1/GIP mechanism appears to provide additional benefits, though comparative cardiovascular outcome data isn't yet available.

Does tirzepatide protect the heart?

Early data shows tirzepatide improves cardiovascular risk factors (blood pressure, lipids, inflammation markers). However, whether this translates to fewer heart attacks and strokes won't be known until the dedicated cardiovascular outcome trial (SURPASS-CVOT) reports results.

Read the original research

Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.

Frontiers in pharmacology, 15, 1453825

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Jingqi; Gu, Yuncheng; Chen, Huaigang; Wang, Hong; Hong, Lang; Li, Bin; Yang, Liu. (2024). Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.. Frontiers in pharmacology, 15, 1453825. https://doi.org/10.3389/fphar.2024.1453825